A major dose-limiting toxicity of some chemotherapeutics (like cisplatin) is nephrotoxicity, leading to acute kidney injury (AKI) in 30% of patients. The aim of my project is to develop a mouse model that recapitulates the dosing regimen humans receive in order to develop and test novel renoprotective agents. This is important as there are no therapeutic interventions for cisplatin-induced AKI, and no long-term studies on kidney function have been performed in mice treated with cisplatin.